Form 4: Haemonetics EVP, Chief Financial Officer James D'Arecca Reports Stock Disposals for Tax Obligations

James D'Arecca, EVP and Chief Financial Officer of Haemonetics, reported disposing of common stock to cover tax obligations related to vesting restricted stock units.

Summary

• James D'Arecca, the EVP and Chief Financial Officer of Haemonetics Corp, filed a Form 4 indicating changes in beneficial ownership.
• On May 15, 2025, Mr. D'Arecca disposed of 622 shares of common stock at a price of $69.38 to cover tax obligations.
• On May 16, 2025, he disposed of 1,246 shares of common stock at a price of $70.31 for the same reason.
• Following these transactions, Mr. D'Arecca beneficially owns 14,824 shares of Haemonetics Corp.
• These shares include unvested Restricted Stock Units (RSUs) previously reported.

Sentiment

Score: 5

Explanation: Neutral sentiment as the filing reflects routine stock disposals for tax purposes, with no indication of strategic shifts or concerns.

Industry Context

Executive stock transactions are common and often related to compensation and tax planning. The disposals are likely a routine part of executive compensation management.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are related to tax obligations and do not indicate a change in the executive's long-term outlook on the company.

Key Dates

Keywords

Form 4, Beneficial Ownership, Haemonetics, DArecca James, Executive Compensation, Stock Disposal, RSUs, Tax Obligations